title: Analysis of small cell lung cancer cell growth inhibition by 13-cis-retinoic acid: importance of bioavailability.
abstract: 13-cis-Retinoic acid can mediate differentiation of transformed cells and slow the proliferation of malignant cells, suggesting its use as a potential intervention tool. Specific cDNA probes for retinoic acid receptors demonstrated the expression of mRNAs for the different retinoic acid receptor isoforms in small cell lung cancer cell lines. Addition of 13-cis-retinoic acid to small cell lung cancer cells cultured using serum-free, hormonally defined medium resulted in a 5-8-fold increase in the level of the retinoic acid receptor-beta mRNAs; in medium containing serum, the increase in expression of the retinoic acid receptor-beta mRNAs was less pronounced, usually no more than 2-fold. Using an in vitro proliferation assay, addition of 13-cis-retinoic acid resulted in a significant dose-dependent, growth-inhibitory effect on the small cell lung cancer cell lines tested using serum-free conditions. These inhibitory effects decreased when cells were cultured in medium containing serum or serum components. Molecular size exclusion chromatography and native gel electrophoresis showed that the causative serum component eluted and migrated with serum albumin. Preincubating serum with triglycerides restored the inhibitory effects of 13-cis-retinoic acid demonstrated in serum-free systems. These data suggest that 13-cis-retinoic acid preferentially binds to serum albumin, restricting its inhibitory effects on epithelial cell receptors. Blocking retinoic acid-albumin interactions with a fatty acid source may improve the bioavailability of 13-cis-retinoic acid and significantly enhance the inhibitory effect in vivo.
authors.affiliation: National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.
authors.forename: I
authors.initials: I
authors.lastname: Avis
authors.forename: A
authors.initials: A
authors.lastname: Mathias
authors.forename: E J
authors.initials: EJ
authors.lastname: Unsworth
authors.forename: M J
authors.initials: MJ
authors.lastname: Miller
authors.forename: F
authors.initials: F
authors.lastname: Cuttitta
authors.forename: J L
authors.initials: JL
authors.lastname: Mulshine
authors.forename: S B
authors.initials: SB
authors.lastname: Jakowlew
mesh_terms: D015152:Blotting, Northern; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002850:Chromatography, Gel; D016895:Culture Media, Serum-Free; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D015474:Isotretinoin / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D018168:Receptors, Retinoic Acid / Q000235:genetics; D012709:Serum Albumin / Q000494:pharmacology; D014280:Triglycerides / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D016895:Culture Media, Serum-Free; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D018168:Receptors, Retinoic Acid; D012709:Serum Albumin; D014280:Triglycerides; C082925:retinoic acid receptor beta; D015474:Isotretinoin